Firm breached fiduciary duty by unfairly allocating losing trades to clients
Firm allegedly touted stocks on social media, while selling its holdings
Exec misled investors by inflating target's revenues to enable SPAC deal
Long-running scheme misled investors on stock markups, fees
Court orders prison, restitution for misappropriating investors' money
Company, executives agree to settle allegations, pay US$41 million
Increase in claimed class-action damages points to larger settlements
Execs falsely inflated firm's revenues to enable acquisition, regulator charges
Ex-CEO misled investors over regulatory approval for new drugs
U.S. authorities allege biostatistician traded on cancer drug data